HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

DOI Web Site Web Site 被引用文献176件

説明

<jats:title>Abstract</jats:title><jats:p>In HLH‐94, the first prospective international treatment study for hemophagocytic lymphohistiocytosis (HLH), diagnosis was based on five criteria (fever, splenomegaly, bicytopenia, hypertriglyceridemia and/or hypofibrinogenemia, and hemophagocytosis). In HLH‐2004 three additional criteria are introduced; low/absent NK‐cell‐activity, hyperferritinemia, and high‐soluble interleukin‐2‐receptor levels. Altogether five of these eight criteria must be fulfilled, unless family history or molecular diagnosis is consistent with HLH. HLH‐2004 chemo‐immunotherapy includes etoposide, dexamethasone, cyclosporine A upfront and, in selected patients, intrathecal therapy with methotrexate and corticosteroids. Subsequent hematopoietic stem cell transplantation (HSCT) is recommended for patients with familial disease or molecular diagnosis, and patients with severe and persistent, or reactivated, disease. In order to hopefully further improve diagnosis, therapy and biological understanding, participation in HLH studies is encouraged. Pediatr Blood Cancer 2007;48:124–131. © 2006 Wiley‐Liss, Inc.</jats:p>

収録刊行物

被引用文献 (176)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ